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The purpose of this study is to evaluate the prognostic value of the combined assessment of multiple molecular markers related to
the epidermal growth factor receptor (EGFR) pathway in resected non-small cell lung cancer (NSCLC) patients. Tumour specimens
of 178 NSCLC patients were collected and analysed for EGFR and KRAS mutation status by DNA sequencing, and for EGFR copy
number by fluorescent in situ hybridisation. Tissue microarrays were generated and used to determine the expression of multiple
EGFR pathway-related proteins by immunohistochemistry. We analysed the association between each marker and patient prognosis.
Univariate analyses for each clinical variable and each molecular marker were performed using Kaplan–Meier curves and log-rank
tests. From these results, we selected the variables KRAS mutations and expression of cytoplasmic EGFR, granular pERK, nuclear
pSTAT3, cytoplasmic E-cadherin and cytoplasmic pCMET to enter into a Cox proportional hazards model, along with stage as the
strongest clinical variable related with prognosis. Of the EGFR-related markers evaluated here, the markers EGFR, pERK, pSTAT3,
E-cadherin, pCMET and mutations in KRAS were associated with survival when analysed in combination in our patient cohort, with
P¼0.00015 as the P-value for a test of the additional impact of markers on prognosis, after taking stage into consideration.
Confirmation of the impact of these markers in independent studies will be necessary.
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Lung cancer is the leading cause of cancer-related deaths
worldwide (Jemal et al, 2006), and non-small cell lung cancer
(NSCLC) represents 85% of lung tumours. The epidermal growth
factor receptor (EGFR) pathway plays a fundamental role in the
carcinogenesis and progression of various tumour types, including
NSCLC (Hynes and Lane, 2005). Epidermal growth factor receptor
(ErbB-1) is a member of the ErbB family of receptors, which also
includes HER2/-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4).
Autophosphorylation of EGFR intracellular tyrosine kinase do-
main results in activation of several downstream signalling
pathways, including the PI3K, STAT and the mitogen-activated
protein kinase pathways pathways, which regulate biological
responses such as proliferation, cell motility, angiogenesis, cell
survival and differentiation (Yarden and Sliwkowski, 2001).
An improved understanding of EGFR signalling has led to the
development of anticancer therapeutics directed against EGFR,
including the tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib (Giaccone, 2005). Objective responses to these agents are
observed in a small subset of unselected NSCLC patients, and
several molecules involved in EGFR signalling have been evaluated
in an effort to identify markers of TKI sensitivity. Such molecular
markers include specific mutations in EGFR or KRAS, EGFR gene
copy number (Lynch et al, 2004; Paez et al, 2004; Cappuzzo et al,
2005; Giaccone, 2005; Pao et al, 2005), the activation status of AKT
and STAT signalling pathways (Sordella et al, 2004), and the
expression level of HER2 (Moasser et al, 2001; Hirata et al, 2005).
More recently, amplification of the CMET receptor (Engelman
et al, 2007), the expression of epithelial to mesenchymal transition
markers, such as E-cadherin and vimentin (Thomson et al, 2005;
Yauch et al, 2005), and the downregulation of HIF-1a have also
been linked to responsiveness to EGFR-targeted agents (Lu et al,
2007).
Although several of these markers have been identified as
potential predictors for response to EGFR TKIs in patients with
advanced NSCLC, some of them have also been shown to be
prognostic for survival, irrespective of treatment. It is important to
be able to distinguish between these two effects.
The presence of EGFR mutations has been proposed to be a
positive prognostic factor (Eberhard et al, 2005), whereas high-
EGFR copy number and the presence of KRAS mutations have
both been associated to poor prognosis in resected NSCLC patients
(Nelson et al, 1999; Hirsch et al, 2003; Massarelli et al, 2007).
Several other markers have also been associated with poor
prognosis in NSCLC (EGFR, CMET, E-cadherin, pAKT (Takanami
et al, 1996; Bremnes et al, 2002; David et al, 2004; Deeb et al, 2004;
Masuya et al, 2004a)), but at present there is no single marker that
can be used to guide therapy or predict prognosis of NSCLC
patients.
Received 6 May 2008; revised 12 August 2008; accepted 20 October
2008; published online 2 December 2008
*Correspondence: Dr G Giaccone; E-mail: giacconeg@mail.nih.gov
British Journal of Cancer (2009) 100, 145–152
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sWe hypothesised that the combined analysis of several of these
molecular markers (Figure 1), which provides information on the
activity/sensitivity of the EGFR signalling pathway at different
points, is related to the prognosis of NSCLC patients when
analysed in combination. Such analysis aids to distinguish the
prognostic implication of the EGFR pathway from its predictive
value in patients treated with agents targeted to this pathway.
Thus, we carried out an analysis of EGFR and KRAS mutational
status, EGFR copy number and the expression of EGFR, HER2,
pCMET, pAKT, PTEN, pSTAT3, pSTAT5, pERK, HIF-1a,
E-cadherin and vimentin, in resected NSCLC patients to assess
their potential combined prognostic significance with respect to
overall survival.
MATERIALS AND METHODS
Patients and samples
Radically resected tumour specimens of 178 NSCLC patients were
collected. For 148 patients, both frozen and paraffin-embedded
tissue was available; for 30 patients only paraffin-embedded
material was available. Samples were obtained from patients
with pathological stage I, II or III and 24% of patients received
(neo-)adjuvant chemo/radiotherapy. A full description of patient
characteristics is provided in Table 1. The study was carried out in
accordance with the medical ethical committee guidelines of VU
University Medical Center, Amsterdam, The Netherlands.
Isolation of genomic DNA
DNA was isolated from frozen tissue (n¼148). Sections of tissue
samples flanking those used for DNA isolation were verified by the
study pathologists (KG and FBJMT) to contain at least 50% of
tumour cells. Genomic DNA was extracted from frozen samples
using trizol, following manufacturer instructions (Life Technologies,
Breda, The Netherlands).
PCR amplification and DNA sequencing
Mutation analysis was carried out on 148 patients for which frozen
tissue samples were available, because paraffin-embedded samples
might yield a higher proportion of false-positive results (Marchetti
et al, 2006; Gallegos Ruiz et al, 2007a), and we avoided using two
different sources of samples (frozen and paraffin) for one type of
analysis. We used 100ng of genomic DNA derived from tumour
cells as template in nested PCR reactions to amplify DNA
fragments corresponding to exons 18–21 of EGFR, and exons 1
and 2 of KRAS. The PCR protocol and the sets of primers have
been described in detail earlier (Janmaat et al, 2006). Polymerase
chain reaction products were purified using a presequencing kit
(Amersham Biosciences, Roosendaal, The Netherlands), and
sequenced with both forward and reverse primers using the
BigDyeTM Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA), using the ABI PRISMt 3100
Genetic analyzer (Applied Biosystems). Non-amino acid changing
mutations were defined as single nucleotide polymorphisms.
Mutations were confirmed by sequencing independent PCR
products.
Fluorescent in situ hybridisation
Fluorescent in situ hybridisation (FISH) was performed only
on frozen sections, as this analysis provides poorer results on
paraffin-embedded tissue (Gallegos Ruiz et al, 2007b). Frozen
sections of 4mm thickness were fixed with methanol/acetic acid
(3:1) and pretreated by digestion with 0.01% pepsin/0.2N HCl at
371C for 2min, and incubated for 10min in 50mM MgCl2/PBS
followed by 10min in 50mM MgCl2/3.7% formaldehyde/PBS. After
2h incubation with 70% formamide/0.6  SSC, the sections were
dehydrated with alcohol. Following pretreatment, 10–15ml LSI
EGFR spectrum orange/CEP7 Spectrum Green probe (Vysis, Abbot
Laboratories, Downers Grove, IL, USA) was applied, the section
was covered with a coverslip and sealed with rubber cement.
Following a denaturation step at 801C for 10min, slides were
placed in a humidified chamber at 371C for 20–24h. Then,
sections were washed with 1.5 M urea/0.1  SSC at 451C for 30min,
and with 2  SSC for 2min. Finally, sections were counterstained
with 40,6-diamidino-2-phenylindole (DAPI, Sanbio BV, Uden,
The Netherlands), dehydrated with alcohol, air-dried and
mounted using Vectashield (Brunschwig Chemie, Amsterdam,
The Netherlands).
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Figure 1 Overview of markers analysed in this study. A graphic display of a selection of EGFR pathway-related markers. The markers analysed in this study
are indicated with an asterisk (
%). Dashed lines indicate hypothesised interactions.
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FISH slides were evaluated using a Leica DMRA fluorescent
microscope (Leica Microsystems BV, Wetzlar, Germany) with a
 60 PL Fluotar oil immersion objective (NA¼1.40). Scoring was
done by two independent observers (KF and MIGR). For every
sample, the complete section was screened for homo/heterogeneity
of the FISH signals. The signals in 200 tumour cells were counted
in at least three representative microscopic fields. The number of
cells having 0, 1, 2, 3, 4, 5 or X6 red signals or clusters was noted,
and samples were categorised as described earlier (Hirsch et al,
2005). Samples were considered as having high-EGFR polysomy
when X4 dots per nucleus were present in X40% of tumour cells,
and as having EGFR amplification when tight EGFR gene clusters
were present in X10% of cells.
Tissue microarray construction
Paraffin-embedded tumour material of 178 patients was cut into
4mm-thick sections and placed onto glass slides. Slides were
stained with hematoxylin and eosin, and a pathologist (KG)
verified the presence of tumour cells and marked the tumour area.
Biopsies of 0.6mm diameter were taken from the donor block, two
from the tumour and one from the normal tissue area surrounding
the tumour. Biopsies from the donor blocks were included in
recipient tissue array blocks using a precision tissue array
instrument (Beecher Instruments, Sun Prairie, WI, USA).
Immunohistochemistry
Tissue microarray (TMA) sections were deparaffinised using
xylene and dehydrated in alcohol. To block the endogenous
peroxidase activity, tissue slides were incubated in methanol/0.3%
H2O2 for 30min. Antigen retrieval was carried out by heating the
slides in 0.1 M sodium citrate or 1mM Tris/ethylene diamine
tetraacetic acid (pH 9.0) for 30min. Sections were then incubated
with the primary antibody overnight at 41C, using sections
incubated with antibody diluent (Immunologic, Duiven, The
Netherlands) as negative control. Sections were developed using
the DAKO Envisiont visualisation system (Dakocytomation,
Heverlee, Belgium). Pretreatment conditions and antibody dilu-
tions are available on request. The phosphorylation status of
CMET and AKT at several residues was analysed using different
phospho-specific antibodies.
Immunohistochemistry scoring
Protein expression determined by immunohistochemistry (IHC)
was evaluated using an Olympus BX50F bright field microscope
(Olympus Optical Co Ltd., Tokyo, Japan) with a  40 plan
objective (NA¼0.65). Scoring was done by two observers (KF and
MIGR). For each protein, intensity (negative: 0, weak positive: 1,
moderately positive: 2, strong positive: 3) and percentage of
positively stained cells were scored. Some cases suffered tissue loss
or lack of tumour cell representation to an extent that precluded
the evaluation of protein expression. The different subcellular
localisation of the proteins was recorded as nuclear (N),
membrane-associated (M) or cytoplasmic (C) (Cheuk and Chan,
2004). For example, a marker described as pCMET.1003.N refers to
CMET phosphorylated at residue 1003 localised in the nucleus. We
also note that, in the particular case of pERK, some samples
showed specific pERK granules in the cytoplasm and were
categorised as pERK.gr. The staining intensity value was multiplied
by the percentage of positive cells (Lagendijk et al, 1998), yielding
a final expression score ranging from 0 to 300.
Statistics
Univariate analyses were done, using standard two-tailed log-rank
tests and individual Kaplan–Meier curves, to serve as a screening
procedure to initially determine which parameters should be
considered for evaluation in a Cox proportional hazards model
(Kaplan and Meier, 1958; Mantel, 1966; Cox, 1972). Groupings for
analyses were formed on the basis of the observed distribution of
the values. After these initial groupings had been done, all of the
clinical, demographic and marker parameters were initially
evaluated in a univariate fashion with respect to survival. In a
limited number of cases, when the results of an exploratory
evaluation identified that there could be a difference in prognosis
by further combining the categories into just two groups of
patients, based on one of the two or three possible cut-points, the
resulting P-value was adjusted by multiplying the unadjusted
P-value by the number of implicit tests performed in order to
arrive at the final division. For example, if the initial Kaplan–
Meier analysis used data in three groups, and two were similar in
prognosis, but one differed from the other two, then the data were
regrouped into the two resulting categories, and the adjusted
P-value was reported to be two times the unadjusted one, as there
were two possible groupings evaluated implicitly, with the best one
selected for further evaluation.
Table 1 Clinicopathological characteristics of the patients included in this
study
n¼178
Characteristics n (%)
Gender
Male 127 (71)
Female 51 (29)
Histology
Adenocarcinoma 64 (36)
BAC 6 (3)
Squamous cell carcinoma 77 (43)
Large cell carcinoma 24 (14)
Others 7 (4)
Smoking status
Never 3 (2)
Former 70 (39)
Current 60 (34)
Unknown 45 (25)
Tumor stage
I 90 (51)
II 52 (29)
III 36 (20)
Treatment
No treatment 133 (75)
Pre-operative chemotherapy 28 (16)
Post-operative chemotherapy 3 (2)
Post-operative radiotherapy 11 (6)
Pre-operative chemo/radiotherapy 3 (1)
Type of surgery
Pneumonectomy 53 (30)
Lobectomy 111 (62)
Bilobectomy 8 (5)
Wedge resection 6 (3)
Resection
Complete resection (R0) 123 (69)
Microscopic residue (R1) 36 (20)
Macroscopic residue (R2) 9 (5)
Uncertain 10 (6)
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analysed in a multivariate analysis using Cox proportional hazards
modelling. Only those parameters with unadjusted P-values of
o0.15 from the univariate analyses were included in an initial Cox
model. A standard backward selection technique, as well as
stepwise selection, was used to identify parameters to be
considered of joint importance in the model. In addition,
a likelihood ratio test was performed to determine the increase
in a given Cox model’s predictive ability following inclusion of
marker values. All P-values are two-tailed, and except as noted
above, have not been adjusted for multiple comparisons. As this is
an exploratory study and not definitive, the findings are intended
to suggest the strength of the evidence that a marker may be
associated with prognosis, and to indicate which markers may
be given greater priority for confirmation in later studies.
RESULTS
EGFR, KRAS mutations and EGFR copy number
EGFR mutation analysis was successful in 136 patients and
mutations were identified in 4% (n¼5) of the patients. Mutations
observed were P848L (n¼1), L858R (n¼1), DelL746-752S (n¼1),
the double mutation E709KþL858R (n¼1) and the double
mutation S768IþL861Q (n¼1). Epidermal growth factor receptor
mutation P848L was not considered to be a cancer-specific EGFR
mutation based on previous findings by us and others (deGunst
et al, 2007; Janne et al, 2006). KRAS mutations were observed in
18% (n¼25) of the 139 patients whose samples could be analysed.
Mutations were predominantly observed in codon 12 (n¼19) but
were also detected in codon 13 (n¼3) and codon 61 (n¼3).
Finally, FISH could be evaluated in 138 patients. Amplification
(tight EGFR signal clusters) was observed in 6% of the patients,
whereas high polysomy, defined as more than four EGFR signals
per cell in more than 40% of cells, was observed in 8% of the
patients. Epidermal growth factor receptor copy number and EGFR
mutation may be related, as out of five EGFR mutant samples, two
samples showed high polysomy and one sample showed EGFR
amplification.
Protein markers
The expression, phosphorylation status and subcellular localisa-
tion of proteins evaluated in 178 patients using the TMA by IHC
are referred to as protein markers. As described in the Materials
and Methods section, for each protein we scored the staining
intensity and the percentage of positively stained cells. In Figure 2,
representative images of immunohistochemical staining for EGFR
(A), pCMET (B-C), E-CADHERIN (D), PTEN (E) and pSTAT3 (F)
are shown.
Univariate analysis
To evaluate the effect of each clinical and molecular or protein
markers separately, we performed univariate analyses using
Kaplan–Meier curves and log-rank tests. Table 2 presents the
results of a univariate evaluation of demographic and clinical
parameters, and their association with overall survival. The type of
resection (R0 vs R1/R2), stage (I vs II vs III or I vs II/III) and use of
pretreatment chemo-radiation, each appear to be sufficiently
associated with survival to be candidates for consideration as
parameters for evaluation in a Cox model. However, because
pretreatment chemo-radiation was performed in only three
patients, this parameter was excluded from further evaluations.
EGFR FISH and mutations in both EGFR and KRAS were also
evaluated to determine whether any of these parameters may be
importance in prognosis (Table 2). KRAS was the only one of this
class of parameters with any potential association with
survival. Surprisingly, the presence of a KRAS mutation was
related, although not significantly, with improved survival, which
EGFR pCMET.1003 pCMET.1349
pSTAT3 PTEN E-cadherin
100 m 100 m 100 m
100 m 100 m 100 m
Figure 2 Representative immunohistochemical staining pattern for several of the markers analysed. Examples of positive stainings of total EGFR on the
membrane, pCMET.1003 on the membrane, pCMET.1349 in the nucleus, E-cadherin on the membrane, tumour cells negative for PTEN with positive
stromal staining and positive pSTAT3 staining in both the cytoplasm and nucleus.
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Miyake et al, 1999).
Individual survival analyses of each protein marker at each
staining site were also performed (Table 2). On the basis of cut-off
P-value of 0.15, the marker parameters, EGFR.C, pERK.gr,
pSTAT3.N, E-cadherin.C and pCMET.1003.C are candidates for
inclusion in a Cox model. Kaplan–Meier curves of each parameter
to be included in the Cox model are shown in Figure 3.
Multivariable analysis
The univariate analysis showed that both stage (I vs II/III) and
resection (R0 vs R1/R2) were of importance in prognosis. As the two
parameters were highly associated with one another (Po0.0001 by
Fisher’s exact test), and by Cox modelling, it was determined that
these parameters could not simultaneously be included in the model
and have a combined significant impact on survival. When models,
which contained either stage or type of resection were constructed,
restricted to the set of patients in which type of resection was known,
the results of the modeling were quite similar (data not shown). As
stage is conventional, widely accepted parameter, the Cox model
incorporating stage will be presented to determine if the molecular
and protein markers retained their prognostic significance after
taking stage into consideration. In Table 3, results from this
multivariate analysis are shown using a backward selection. This
model is derived from the subset of 116 patients who were not
missing any data on the parameters in the model or on the type of
resection. Using a stepwise selection model, we were also able to
show that pERK.gr was associated with survival adjusting for other
markers (data not shown). Further, to show that the markers
contributed prognostic information beyond stage, a likelihood ratio
test was performed. On the basis of backward selection model, the
parameters KRAS mutation, EGFR.C, ECADHERIN.C, pSTAT3.N
and pCMET.1003.C added significantly in prognostic ability
(P¼0.00015) beyond stage alone. Thus, these would be markers,
which may be of higher priority to consider evaluating in a
subsequent, more definitive study.
As the patients included in this study are somewhat hetero-
geneous with respect to stage, a further subset analysis was
performed to determine if there are markers, which are jointly
associated with prognosis in patients with stage I disease only, the
predominant subset of patients. After a univariate screening
procedure was conducted, only pSTAT3.N, EGFR.C and vimen-
tin.N were each associated with a trend towards association
with survival (Po0.10 for each). When evaluated in a Cox model
with backward selection, only vimentin.N emerged as a marginally
significant parameter using 0.05 as the traditional threshold for
inclusion in a final model (P¼0.055, hazard ratio¼4.10).
DISCUSSION
At present, the pTNM staging is regarded as the most reliable
prognostic factor for NSCLC (Watanabe, 2003). However, staging
alone is unable to correctly predict survival in a significant
proportion of patients who undergo radical resection. The use of
biological markers has been investigated as a way to increase the
ability to estimate prognosis in patients. In the study described
here, stage was indeed related to prognosis of NSCLC patients, as
was type of resection. Immunohistochemical expression of
cytoplasmic EGFR, cytoplasmic E-CADHERIN, nuclear pSTAT3,
cytoplasmic CMET, granular pERK and KRAS mutations jointly
added prognostic significance to stage.
Much effort is currently ongoing to identify biomarkers that are
prognostic for survival, and also to identify markers that are
predictive of response to systemic therapies. Complementary DNA
microarray technology has been widely used to this end, but this
technique is still far from clinical implementation mainly due to
the need for validation and standardisation across laboratories,
and also due to the high costs. Immunohistochemistry, on the
other hand, is a widely accepted technique of assessing protein
expression with much lower costs than microarrays, although
validation and standardisation are also critical issues. However, it
is also known that prognostic markers based on IHC can provide
inconsistent or contradictory results, owing to the use of different
antibodies and processing methods (Atkins et al, 2004; Baker et al,
2005), as well as different scoring and categorisation systems. All
these issues emphasise the need for standardised processing and
scoring procedures. In addition, as quantitation is subjective and
subcellular localisation may matter (Cheuk and Chan, 2004), it
Table 2 Univariate association between individual parameters and survival
Clinical and demographic markers Genetic markers Protein markers
P-value per subcellular localisation
Parameters P-value Parameters P-value Parameters Membranous Cytoplasmic Granular Nuclear
Age 0.49
R0 vs R1/R2 0.057 EGFR FISH EGFR 0.63 0.10 (0.099
a)— 0
Adenocarcinoma vs all other 0.54 No gain vs other 0.15 HER2 1 0.33 — —
BAC vs all other 0.43 High polysomy vs other 0.13 pAKT.473 — 0.22 — 0.62
Squamous cell vs all other 0.42 Amplification vs other 0.72 pAKT.309 0.53 1 — 0.95
Large cell carcinoma vs all other 0.9 PTEN — 0.63 — 0.69
Smoking (non vs current vs Former) 0.79 EGFR mutation pERK — 0.36 0.011 0.39
Stage (I vs II vs III) 0.04 WT vs other 0.15 pSTAT3 0.97 0.50 — 0.056 (0.11
b)
Stage (I vs II/III) 0.015 (0.03
c)S N P vs other 0.70 pSTAT5 0.76 0.31 — 0.33
Pre-operative CT vs not 0.45 Mutant vs other 0.33 E-cadherin 0.32 0.031 — —
Post-operative CT vs not 0.5 Vimentin 0.29 0.80 — 0.45
Post-operative RT vs not 0.15 KRAS mutation HIF-1a — — — 0.55
Pre-operative chemo-radiation vs not 0.031
d WT vs other 0.08 pCMET.1003 0.8 0.11 — —
Other diseases vs not 0.37 SNP vs other 0.84 pCMET.1349 — 0.49 — 0.69
Mutant vs other 0.08 pCMET.1230 0.88 0.90 — 0.68
pCMET.1365 0.55 0.87 — 0.86
Abbreviations: CT¼chemotherapy; EGFR¼epidermal growth factor receptor; FISH¼fluorescent in situ hybridization; R0, R1, R2¼resection1, 2, 3; RT¼radiotherapy;
SNP¼single nucleotide polymorphism; WT¼wild type.
aEGFR C: P¼0.10 for 0–100 vs 160–300; P¼0.20 after adjustment for new division in data.
bpSTAT3 N: P¼0.056 for
0–200 vs 210+; P¼0.11 after adjusting P-value.
cP¼0.03 after adjustment for tests leading to re-grouping.
dOnly three patients received pre-operative chemo-radiation; thus
this parameter will not be considered in any other analyses.
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detail. In this study, we have used resection specimens to perform
IHC on TMAs to identify protein expression, and we have scored
the staining intensity, the percentage of positive cells and the
subcellular localisation of proteins, in order to present our data in
the most complete manner.
Given the importance of EGFR-mediated signalling in NSCLC,
various EGFR pathway-related proteins have already been studied
as potential markers using IHC in NSCLC tumour samples. Several
downstream proteins have been shown to provide some prognostic
information, such as E-cadherin, EGFR (Bremnes et al, 2002; Deeb
et al, 2004) and pAKT (David et al, 2004), although none of them
has proven to be sufficiently useful in clinical diagnostics in terms
of prediction of response to treatment or prognosis. As
simultaneous analysis of various markers could potentially
increase prognostic significance over individual markers, we have
used a multi-marker approach, using TMAs, to investigate the
relevance of several EGFR pathway-related markers and their
association with NSCLC patient prognosis.
Here, we also show that high expression of pCMET is related
to poor prognosis and high expression of E-cadherin is related to
improved outcome (Bremnes et al, 2002; Masuya et al, 2004b). We
found KRAS mutations to be related to favourable prognosis,
which contrasts the existing literature that indicates these
mutations to be a negative prognostic factor (Van Zandwijk
et al, 1995; Miyake et al, 1999). However, this prognostic effect of
KRAS mutations is mainly observed in adenocarcinomas of the
lung (Slebos et al, 1990; Mitsudomi et al, 1991; Sugio et al, 1992).
Here we analysed the effect on survival of NSCLC patients in a
population with both adenocarcinoma (36%) and squamous cell
carcinoma (43%) histologies. In this patient cohort, patients with
adenocarcinoma histology show improved survival as compared
with the squamous cell carcinoma histology. As KRAS mutations
were mainly observed in patients with adenocarcinoma histology,
this could have been confounding the favourable prognostic effect
we observe for KRAS mutations. The negative prognostic effect of
KRAS mutations could also not be confirmed in other studies
analysing bigger groups of patients with equally balanced
adenocarcinoma vs squamous cell carcinomas (Moldvay et al,
2000; Schiller et al, 2001; Tsao et al, 2007). We also observed that
high expression of nuclear pSTAT3 was related to improved
survival. pSTAT3 expression has previously been reported to be
associated with smaller tumours and limited smoking history
(Haura et al, 2005). According to this observation, it may be
argued that pSTAT3-activated tumours represent a more indolent
tumour type. Activation of the STAT pathway has also been
associated with EGFR mutations (Sordella et al, 2004), and has
been proposed as a marker to identify patients to be treated with
EGFR TKIs. The low prevalence of EGFR mutations in our patient
cohort (4%) precluded the study of such an association in our
study. Another interesting observation was the presence of a
specific granular staining pattern for pERK, which was related with
improved prognosis. Upon further analysis, this specific staining
pattern was found to be correlated with the presence of KRAS
mutations (see Supplementary information for details). The
molecular basis for this correlation remains to be elucidated.
In summary, we showed that KRAS mutation, EGFR.C,
E-cadherin.C, pSTAT3.N, pCMET.1003.C and pERK.gr were
markers that were associated in a combined fashion with survival
of NSCLC patients after taking stage into consideration. The good
predictive value of EGFR mutations and poor predictive value of
KRAS mutations with regard to EGFR TKI treatment was not
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Figure 3 Survival across the strata determined by eight markers. Kaplan–Meier curves showing the effect on survival of univariate analysis of the variables
selected to be included in the Cox model.
Table 3 Prognostic significance from Cox model using backward
selection
Variable
Parameter
estimate P-value
Hazard
Ratio
95% CI
for HR
Stage (I vs II/III) 0.55 0.035 1.73 1.04–2.87
KRAS mutation  0.95 0.016 0.39 0.18–0.84
EGFR C 0.9 0.015 2.45 1.19–5.02
E-cadherin.C  0.96 0.0069 0.38 0.19–0.77
pSTAT3.N  1.18 0.0006 0.31 0.16–0.60
pCMET.1003.C 0.78 0.0049 2.16 1.27–3.73
Abbreviations: EGFR¼epidermal growth factor receptor; CI¼confidence interval;
HR¼Hazard ratio.
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sreflected in terms of prognosis in our patient cohort. This study
was conducted in an exploratory manner and the results may not
be applicable to patients who receive adjuvant chemotherapy
that has recently become standard for stage II and III disease.
Confirmation of the impact of these markers in independent,
adequately sized studies is necessary before considering these
markers to be used for future evaluation of patient prognosis in
clinical practice.
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